This study included 97 patients (57 had cardiac transthyretin amyloidosis, 20 had cardiac light chain amyloidosis, 3 had ApoA1 or ApoA4, 8 had systemic amyloidosis but no cardiac involvement, and 17 ...

Phase 3 – REVEAL study with 124 I-evuzamitide in patients with suspected cardiac amyloidosis is ongoing by Brigham and Women’s Hospital, Boston, MA. AT-05 (99mTc-p5+14), a radiotracer ...

Although advances have been made in the development of techniques to detect biomarkers of early Alzheimer's disease, such as amyloid- β and tau proteins, these indicators do not fully explain the ...

Finally, an ear, nose and throat doctor biopsied her tongue and figured out what caused her headaches — Stage 4 tongue cancer. “It wasn’t until I saw a specialist that I found out what I was ...

Van Halen died of cancer at age 65 in October. “I used metal picksthey’re brass and copperwhich I always held in my mouth, in the exact place where I got the tongue cancer,” he told Billboard prior to ...

A burnt tongue is a common problem that can result from eating or drinking something too hot, exposure to factors such as chemical burns, or smoking. While most symptoms of a burnt tongue can be ...

For the study, researchers recruited 73 people with rare and inherited genetic mutations that cause the overproduction of a protein called amyloid in the brain. In case you’re not familiar ...

(AP Photo/Heather Khalifa) Jake Heinrichs prepares for his infusion treatment with an experimental anti-amyloid Alzheimer’s drug while at home in New York, on Wednesday, March 12, 2025. (AP ...

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

Gantenerumab helps eliminate one of the neurological hallmarks of Alzheimer’s, called amyloid plaques. For some participants, gantenerumab reduced their risk of developing the disease by more ...

One year earlier, in June 2021, the US Food and Drug Administration had approved aducanumab, an antibody-targeting beta-amyloid, as a treatment for Alzheimer's, even though the data supporting its use ...

The agency cleared the drug, called Amvuttra, for people with a cardiac form of the rare disease transthyretin amyloidosis. Alnylam already sells the therapy for individuals with a genetic type of the ...